Overview

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Status:
Recruiting

Trial end date:
2030-02-25

Target enrollment:

Participant gender:

Summary

Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing InnoCare Pharma Tech Co., Ltd.

Treatments:

Lenalidomide
Rituximab